Carrie M. Hersh

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

Medicine, Pharmacology, Pharmacotherapy +11

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

Ellen M. Mowry, Robert Bermel, James R. Williams et al. · Frontiers in Neurology · 2020 · 90 citations · Full text

Medicine, Health Systems, Neurology +12

Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol

Daniel Ontaneda, Emma Tallantyre, Praneeta Raza et al. · Contemporary Clinical Trials · 2020 · 71 citations · Full text

Pharmacy, Neurology, Outcomes Research +9

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up

Carrie M. Hersh, Thomas E. Love, Samuel Cohn et al. · Multiple Sclerosis and Related Disorders · 2016 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up

Carrie M. Hersh, Thomas E. Love, Anasua Bandyopadhyay et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2017 · 42 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +10